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Background: Clusterin is, in its major form, a secreted heterodimeric disulfide-linked glycoprotein (sCLU), which
plays important roles in cell survival and death. In laryngeal squamous cell carcinomas (LSCC), sCLU is up-regulated
and its expression is related to the invasiveness of these tumors. The purpose of this study was to explore the
inhibiting role of sCLU gene silence in the invasive ability and growth of Hep-2 human laryngeal squamous
carcinoma cells (Hep-2) by transfection of short hairpin RNA expression plasmids against sCLU (sCLU-shRNA)
(in vivo) or small interference RNA (sCLU-siRNA) (in vitro).
Methods: sCLU-siRNA and the control siRNA were transfected into Hep-2 cells using Lipofectamine 2000. RT-PCR
and Western blot were used to detect the effect of siRNA transfection on sCLU mRNA and sCLU protein expression.
The invasive activity of sCLU-siRNA-transfected Hep-2 cells was measured with the modified Boyden chamber assay
and wound healing assay. The effects of sCLU-siRNA on cell proliferation were evaluated by MTT assay. Apoptosis
was measured by Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double-staining methods. We
next evaluated the effects of sCLU silencing by sCLU-shRNA transfection in vivo on tumor growth and metastatic
properties to the lung. Terminal deoxytransferase-mediated dUTP nick end labeling (TUNEL) staining was used to
observe the apoptosis in the xenografts.
Results: It showed that siRNA-mediated down-regulation of sCLU expression in Hep-2 cells significantly inhibited
cell proliferation and promoted apoptosis in vitro. Furthermore, siRNA-mediated down-regulation of sCLU expression
decreases in vitro cell migration and invasion ability. In vivo, the average volume of tumors in the sCLU-shRNA
transfected group was significantly lower than in the control group (P <0.01), and the significant apoptosis detected
with TUNEL was indicated in the sCLU-shRNA transfected groups (P <0.05). Significantly, we found that sCLU-shRNA
could exert marked inhibition of the lung metastasis of Hep-2 cells in nude mice in vivo.
Conclusions: sCLU gene silence can inhibit invasion and growth of LSCC. sCLU may provide a potential
therapeutic target against human LSCC.
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Laryngeal cancer is the 11th most common cancer world-
wide. Laryngeal squamous cell carcinomas (LSCC) repre-
sent approximately 85 to 90% of all the malignant tumors
of the larynx [1]. Although early-stage laryngeal cancer is
often cured by surgery or radiotherapy, for the majority of
patients with the advanced disease, the outcome has not
improved in the last three decades. In addition, surgery
might lead to complete or partial loss of vocal function
and many patients have to maintain a tracheal cannula for
life due to total laryngectomy. Therefore, a better under-
standing of the molecular mechanisms of LSCC progres-
sion and a new strategy for the treatment of LSCC are in
urgent demand.
Clusterin is, in its major form, a secreted heterodimeric
disulfide-linked glycoprotein (sCLU). It was first linked to
cell death in the rat ventral prostate after androgen
deprivation [2]. sCLU overexpression reaches a maximum
at three to four days post-castration and coincides with the
onset of massive cell death [3]. The sCLU level also rises in
various malignant tumors, including gastric cancer [4],
ovarian cancer [5], breast cancer [6], bladder cancer [7],
colorectal cancer [8], hepatocellular carcinoma [9], prostate
cancer [10] and laryngeal squamous cell carcinomas [11].
In these cancers, sCLU overexpression has been reported
to be closely associated with cancer development and pro-
gression. Introducing the sCLU gene into renal cell car-
cinoma cells or hepatoma cells enhances their metastatic
potential and causes enhanced formation of metastatic
nodules in experimental animals [9,12]. Moreover, small
interference RNA-mediated sCLU gene silencing inhibited
invasion and metastasis in breast cancer cells [13,14], lung
cancer cells [15,16] and prostate cancers [17].
sCLU has also been described as an anti-apoptotic fac-
tor. Miyake et al. [18] have demonstrated that the overex-
pression of sCLU in human androgen-responsive prostate
cancer cells (LNCaP) by stable transfection rendered them
highly resistant to androgen ablation, and the introduction
of antisense testosterone-repressed message-2 oligodeoxy-
nucleotide therapy in the Shionogi tumor model induces
apoptosis and tumor regression. Moreover, small interfer-
ence RNA-mediated sCLU gene silencing in osteosarcoma
and breast cancer induces significant reduction of cellular
growth and increases cellular apoptosis [19-21].
Previous study found sCLU was overexpressed in laryn-
geal carcinomas, and clusterin expression was significantly
related to the degree of local invasion [11]. However,
whether sCLU may be a target for the treatment of laryn-
geal carcinomas has not been elucidated. In the present
study, we sought to investigate the effect of sCLU expres-
sion inhibition by using small interfering RNA (siRNA) and
short hairpin RNA expression plasmids (shRNA) in Hep-2
cells on invasion, metastasis, apoptosis and proliferation
in vitro and in vivo. Our findings indicate that knockingdown the sCLU protein in Hep-2 cells by using siRNA in-
duces growth retardation that is accompanied by higher
rates of spontaneous endogenous apoptosis in vitro, and
decreases in vitro cell migration and invasion ability.
Moreover, sCLU silencing by using shRNA inhibits in vivo
lung metastasis, tumor growth and induces apoptosis.
Methods
Cell culture
Laryngeal carcinoma Hep-2 cells (ATCC) were cultured
in RPMI-1640 medium (GIBCO/BRL, Gaithersburg,
Md, USA) supplemented with 10% new-born calf serum
(GIBCO/BRL) with 100 U/ml penicillin and 100 μg/ml
streptomycin at 37°C in a homeothermic incubator with a
5% CO2 atmosphere. The medium was changed every two
or three days.
siRNA transfection
Hep-2 cells suspended in DMEM with 10% FBS were
added to each well of six-well plates. The plates were incu-
bated at 37°C in a humidified atmosphere of 5% CO2.
After the cell confluence reached 80% in each well,
50 nmol/L of sCLU-siRNA: AUGCCCUGUCUUACU
GUCA or scramble sequences and 10 μL of LipofectA-
MINE 2000 (Invitrogen,Shanghai,China) were added to
Opti-MEM (Life Technologies,Beijing,China) and mixed.
After incubation, the siRNA and LipofectAMINE 2000 so-
lutions were gently mixed and added to the plates. Each
plate was incubated for 48 h until it was ready for further
assay. The knockdown effect was verified by RT-PCR and
Western blot analysis.
Stable shRNA transfection
Short hairpin RNA against sCLU RNA (sCLU-shRNA)
and control plaismid were purchased from Santa Cruz
Biotechnology, Santa Cruz, CA, USA. When they were
at 80% to 90% confluence, Hep-2 cells were transfected
with the plasmids using the Lipofectamine 2000 accord-
ing to the manufacturer's protocol. The stable clones
(Hep-2/sCLU-shRNA and control Hep-2/shRNA) were
selected by culturing transfected cells in the presence of
400 μgml−1 G418 (InvivoGen) for 10 days. Stable pooled
populations of Hep-2/sCLU-shRNA and control Hep-2/
shRNA cells were maintained in culture using 200 μgml−1
of G418. The knockdown effect was verified by RT-PCR
and Western blot analysis.
Western blots
The cells were washed after transfection with sCLU-
siRNA or control siRNA for 48 h in the Hep-2 cells. Cell
lysates were prepared by applying 400 μL lysis buffer
(10 mmol/L Tris–HCl (pH 8.0), containing 150 mmol/L
NaCl, 1 mmol/L phenylmethylsulfonyl fluoride, and 1%
Triton X-100) to confluent cells grown in 60 mm dishes.
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Tris-Glycine gradient denaturing polyacrylamide gels
(Invitrogen) in a 1% SDS-PAGE buffer (1 g/L SDS, 3 g/L
Tris base and 14.4 g/L glycine). Proteins were transferred
to polyvinylpyrrolidine difluoride membranes electrophor-
etically and incubated overnight at 4°C in Blotto (5% dry
milk in 1% TBS (0.9% NaCl, 10 mmol/L Tris (pH 7.4), and
0.5% MgCl2)). Membranes were incubated for 60 minutes
at room temperature with anti-sCLU antibody (Santa Cruz
Biotechnology) overnight at 4°C. The membrane was incu-
bated with a 1:4,000 dilution of horseradish peroxidase-
linked anti-mouse secondary antibodies. The immune
complexes were detected using ECL Western blot detec-
tion reagents. The membranes were stripped of bound
antibody and reprobed with an anti-β-actin antibody to
confirm equal loading of the samples.
RNA extraction and RT-PCR
After transfection with sCLU-siRNA or control siRNA for
48 h in the Hep-2 cells, the total RNA was extracted from
the cells using Trizol reagent (Invitrogen). cDNAs were
synthesized using a ThermoScript RT-PCR system accord-
ing to the manufacturer's instructions (Invitrogen). Two
oligonucleotides (5′-AGATCAGCGCCTGAGAAGCT-3′
and 5′-GGGACCAGTGTACCTTCTCG-3′) were used
as specific primers to amplify the human sCLU sequence.
The human β-actin cDNA fragments were amplified by
the primers 5′-GCTCGTCGTCGACAACGGCT-3′ and
5′-CAAACATGATCTGGGTCATCTTCTC-3′. The PCR
products were separated on 2% agarose gels and the dens-
ity of each product was measured.
MTT assays
MTT was dissolved in phosphate-buffered saline (PBS)
and adjusted to a final concentration of 5 mg/ml. For
MTT assays, Hep-2 cells transfected with sCLU-siRNA or
control siRNA for 48 h (4 × 103/well). Then 20 μl MTT
was added to each well. After an additional 4 h at 37°C,
culture media was removed and 150 μl DMSO was added.
Plates were swirled gently in the dark for 10 minutes at
room temperature (RT). Absorbance values at 490 nm
(A490) for each well in 24 to 96 h were then measured
using an enzyme-linked immunosorbent detector. Based
on these data, cell growth inhibition ratios were calculated
according to the following formula:
cell growth inhibition ratio %ð Þ
¼ control group A value–experimental group A valueð Þ=
control A value%
Annexin V-FITC/PI double-staining
A total of 3 × 105 Hep-2 cells, which was transfected with
sCLU-siRNA or control siRNA for 48 hs, was collectedand washed with PBS. Five microliters of Annexin V-FITC
and 4 μl of PI were added and incubated at room
temperature for 15 minutes and cells were then analyzed
by flow cytometry. Cells were collected by the CellQuest
system (USA) and the apoptosis rate was analyzed with
the ModFit LT for Mac V3.0 software system (Verity
Software House, USA). The apoptosis detection kit was pur-
chased from Beijing Baosai Technology Company (China).
Matrigel invasion assays
In vitro invasion assays were performed by using a
24-well invasion chamber coated with Matrigel (Becton
Dickinson). Hep-2 cells were transfected with sCLU-
siRNA or control siRNA for 24 h, then were trypsinised,
washed with PBS, suspended in DMEM containing 5%
bovine serum albumin (BSA), and plated in the invasion
chamber (3 × 104 cells per well). The lower chambers
were filled with DMEM containing 5% BSA with 2.5%
fetal bovine serum. After 24 h, the cells remaining in the
upper chamber were removed by scraping, whereas the
cells that invaded through Matrigel were fixed and
stained by using 0.5% crystal violet in methanol. All in-
vading cells were counted by microscopic visualisation.
The cell invasions were performed by extracting the
crystal violet dye with dimethylsulphoxide followed by
spectrophotometry at 590 nm. All analyses were per-
formed in triplicate.
Wound healing assay
Hep-2 cells transfected with sCLU-siRNA or control
siRNA for 48 h were grown to confluence in 35-mm tissue
culture dishes. Cell monolayers were scratched using a
micropipette tip, and floating cells were removed by exten-
sive washing with DMEM. Photographs of the wounded
area were taken immediately after making the scratch (0 h
time point) and after 20 h to measure the migration rate
of cells into the wounded area. At least 15 different fields
were randomly chosen across the wound length.
Subcutaneous xenografted tumor model
All the experiments were performed under the approval of
the Animal Experimentation Committee of Linyi city’s
hospital. Female SCID mice, each four to six weeks old,
were obtained from Shandong University. All animals
were maintained in a sterile environment and cared for
within the laboratory animal regulations of the Ministry of
Science and Technology of the People’s Republic of China.
Full details of the study were approved by the ethics
committee at the Junan County Hospital. A suspension of
2 × 106 cells (Hep-2 cells, sCLU-shRNA/Hep-2 cells and
control shRNA/Hep-2 cells, respectively) in 50 μL volume
was injected subcutaneously into the left posterior flank
of mice by use of a 1-cc syringe with a 27½-gauge nee-
dle. Tumors were grown for 28 days. Tumor size was
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calculated as 0.5 × the longest diameter × width2. The
percentage of tumor inhibition was calculated according
to the formula [1 − (T/C)] × 100, where T and C repre-
sent the mean tumor volumes of the treatment group
and the control group, respectively. Immunohistochem-
ical staining and terminal deoxytransferase-mediated
dUTP nick end labeling (TUNEL) staining for tumor
tissues were done according to the method presented
below.Immunohistochemistry in vivo
The primary tumor was harvested, fixed in 4% formalin
and embedded in paraffin. Three-micrometer-thin tissue
sections were obtained and stained for sCLU according
to the manufacturer’s instructions.In situ TUNEL assay
TUNEL staining for tumor tissue was based on the
protocol of the Dead End Colorimetric TUNEL System
(Promega). Briefly, cryostat sections were fixed in 4%
paraformaldehyde, and in situ TUNEL assay was done as
described by the manufacturer (Roche Molecular
Biochemicals, Manheim, Germany). The number of
apoptotic cells was determined in relation to the total
number of cells.Lung metastasis model of nude mouse
In order to induce lung metastasis, Hep-2 cells, sCLU-
shRNA/Hep-2 cells and control shRNA/Hep-2 cells
(1 × 106 cells/mouse) in 100 μL of PBS were injected into
the mice’s tails for 21 consecutive days. After 21 days,
the mice were sacrificed, and the lungs were fixed in
Bouin’s solution. Lung tumors were then analyzed by
obtaining a surface naked tumor count.Figure 1 Effect of sCLU-siRNA transfection on mRNA and protein exp
in Hep-2 cells transfected with sCLU-siRNA. Blots were re-probed with β-actin
RT-PCR analysis shows mRNA expression of sCLU in Hep-2 cells transfected w
was used as an internal control. This is a representative example with mean d
transfectants. sCLU, Clusterin; siRNA, small interference RNA.Statistical assay
All data were displayed by mean ± standard deviation (SD)
and produced by SPSS11.5 statistical software (SPSS Inc.,
Chicago IL, USA). Variance analysis was performed for
the comparison of multiple groups. Group-group com-
parison was carried out with the Student-Newman-Keuls
method (SNK), and a P <0.05 was considered a statistically
significant difference.Results
Knockdown of sCLU results in specific attenuation of
sCLU
sCLU-siRNA and control siRNA were transiently trans-
fected into Hep-2 cells by use of Lipofectin 2000 for
48 h. The cells were collected and protein extracts were
made from the cytoplasm. Protein levels of sCLU were
analyzed by Western blot. As shown in Figure 1A, sCLU
protein was overexpressed in the Hep-2 cells, in the
sCLU-siRNA transfected Hep-2 cells, and sCLU protein
was completely inhibited; however, control siRNA trans-
fection did not induce a significant change in expression
of sCLU in the Hep-2 cells. A sCLU mRNA assay by
RT-PCR has the same results as shown above (Figure 1B).Knockdown of sCLU inhibited proliferation and
stimulated apoptosis of Hep-A2 cells
As shown in Figure 2A, knockdown of sCLU by sCLU-
siRNA significantly inhibited Hep-2 cell growth deter-
mined by MTTassay over four days. These results indicate
that sCLU silencing is overall an effective inhibitor of
Hep-2 cell growth. Knockdown of sCLU-induced cell
death was further confirmed by flow cytometry (Figure 2B).
AnV+/PI− represents cells with early apoptosis - AnV−/PI+
with early necrosis, AnV+/PI+ with a mixture of apoptosis
associated with secondary necrosis and late necrosis, and
AnV−/PI− with live cells. No significant difference wasressions of sCLU. A. Western immunoblot analysis of sCLU expression
antibody to analyze the equal loading of proteins. B. Semiquantitative
ith sCLU-siRNA. Scrambled siRNA was used as a control in parallel. β-actin
ensitometric values from triplicate blots. *, P <0.05 versus control siRNA
Figure 2 sCLU siRNA-mediated suppression of proliferation and increase of apoptosis in the Hep-2 cells. A: The effect of sCLU silencing
on proliferation in Hep-2 cells by MTT assay. The values represent the mean ± SE, n = 3. B: cells were stained with AnV and PI, analyzed by flow
cytometry, and the percentages of cells in groups AnV+/PI − (early apoptosis), AnV−/PI+ (early necrosis), AnV+/PI+ (mixture of apoptosis associated
with secondary necrosis and late necrosis), and AnV−/PI− (live cells) were measured. The values represent the mean ± SE, n = 3.
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Hep-2 cells (data not shown).
Knockdown of sCLU inhibits invasion of Hep-2 cells
in vitro
We tested whether sCLU knockdown affected the invasion
capabilities of Hep-2 cells by using an in vitro invasion
assay. Cells were seeded in the upper part of a Matrigel-
coated invasion chamber in a 5% FCS concentration. After
24 h, the cells remaining in the upper chamber were re-
moved by scraping, whereas the cells that invaded through
Matrigel were fixed and stained by using 0.5% crystalFigure 3 sCLU silencing inhibits invasion of human Hep-2 cells in vitr
sCLU siRNA and control siRNA. At bottom is the quantification of migratory
experiment was done in triplicate and the value obtained from control siRN
scratched in a confluent cell layer of Hep-2 cells. Cells were either transfect
of coverage after 24 h of wound healing is depicted in the graphs for Hep
Hep-2 cells. Significance was determined with a Student's t-test vs control,violet in methanol. In sCLU-silenced Hep-2 cells, invasion
was significantly reduced (Figure 3A).
To analyze the effect of sCLU knockdown on wound
healing, a scratch assay was performed with Hep-2 cells.
In control siRNA transfected Hep-2 cells, 90.6% (±11.74)
of the wound was closed after 24 hours. In contrast, in
sCLU siRNA transfected Hep-2 cells, only 48.4% (±10.2)
of the wound was closed (Figure 3B).
Effects of sCLU shRNA on xenograft tumor growth
As shown in Figure 4, on the 21st day, the average
tumor volume in each group was as follows: controls,o. A. The bar shows the number of migratory cells transfected with
cells in control siRNA and sCLU siRNA transfected Hep-2 cells. The
A transfected cells was set as 100% migration. B. A wound was
ed with control siRNA (control) or sCLU siRNA for 24 h. The percentage
-2 cells. Knockdown of sCLU significantly reduces wound healing in
* P <0.05. sCLU, Clusterin; siRNA, small interference RNA.
Figure 4 The growth curve of subcutaneous tumors. Tumor growth was strongly suppressed following sCLU shRNA transfection compared
with control shRNA and control. Asterisks indicate P < 0.01. sCLU, Clusterin; shRNA, short hairpin RNA.
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sCLU shRNA, 71.3 ± 7.8 mm3. The tumor size in group
sCLU shRNA mice was significantly smaller compared
to the control, with a tumor inhibition ratio of 72.3%.
Statistical analysis revealed no significant difference be-
tween the negative control shRNA and the control
group (P > 0.05), thereby suggesting that the control
plasmids had no obvious side effect on tumor growth.Apoptosis in xenograft tumors
In the tumors transfected with sCLU-shRNA, 12% of
tumor cells were TUNEL-positive (Figure 5). However,
only 1 to 2% of apoptotic cells were found in the tumors
transfected with the control shRNA and the saline control.
There were significantly more apoptotic cells in the sCLU-
shRNA group than in the control shRNA and saline-
treated groups.The expression of sCLU in xenograft tumors
In the tumors transfected with the control shRNA, the
sCLU protein was significantly higher (data not shown).
However, the sCLU protein was significantly decreased
in the majority of the tumor cells from mice that were
transfected with sCLU shRNA by immunohistochemical
assay (data not shown).Figure 5 Apoptosis in subcutaneous tumors. In the tumors treated with
only a few apoptotic cells were found in the tumors treated with the cont
higher than that of the control groups. Asterisks indicate P <0.01. sCLU, Cluste
dUTP nick end labeling.sCLU silencing inhibits Hep-2 cells lung metastasis
In the sCLU shRNA transfected groups, lack of sCLU had
a significant effect on development of lung metastasis with
a 66.4% reduction in surface tumor number (control
shRNA groups’ median tumor number = 62.4 ± 6.7; sCLU
shRNA transfected group’s median tumor number =18.6 ±
4.3; Figure 6).
Discussion and conclusions
RNA interference (RNAi) is a sequence-specific post-
transcriptional gene silencing tool [22]. The process of
gene-specific silencing through destruction of its mRNA
transcript can be triggered by endogenous or exogenous
small interfering RNAs (siRNAs) [23]. Long double-
stranded mRNAs derived from endogenous gene tran-
scription or transfected transgene plasmids present in the
cytoplasm can trigger the cleavage activity of the intracel-
lular enzyme, Dicer, to cut mRNA into 19-nucleotide pairs
with two nucleotide overhangs at both 3’-ends, called
small interfering RNA (siRNA) [24]. Gene silencing using
siRNA has several advantages intrinsic to RNAi, such as
its high specificity, intrinsic biological response [25], and
more efficient and specific silencing effects with lower
dosing requirements, compared to antisense-based gene
silencing [26]. However, single-dose siRNA silencing ef-
fects are transient (up to five days in dividing cells) [23]
and lipid-based siRNA delivery complexes can be rapidlysCLU shRNA, significant TUNEL-positive cells were found. However,
rol shRNA and the saline. The apoptotic index of sCLU shRNA was much
rin; shRNA, short hairpin RNA; TUNEL, terminal deoxytransferase-mediated
Figure 6 The effect of sCLU shRNA on lung metastasis. This is a representative histogram showing the surface tumor number in three
groups. Each bar represents mean ± SE; *, P <0.01. All experiments were repeated three times with similar results. sCLU, Clusterin; shRNA, short
hairpin RNA.
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specificity. Therefore, we used siRNA against sCLU to
study the effect of sCLU in vitro for its short duration.
Apoptosis plays an essential role as a protective mech-
anism against carcinogenesis by eliminating genetically
damaged cells - initiated cells as well as those cells that
have progressed to malignancy. Our presented results
clearly demonstrate that sCLU mRNA and protein is
amenable to specific siRNA-induced degradation in vitro.
Moreover, it is evident that the primary function of sCLU
in Hep-2 cells is anti-apoptotic. In Hep-2 cells, sCLU
knockdown resulted in significant growth retardation,
higher rates of endogenous apoptosis and reduced meta-
static potential. Interestingly, it was recently shown that
sCLU overexpression into human renal cell carcinoma
cells enhances their metastatic potential [12]. Whether
sCLU overexpression could enhance the metastatic poten-
tial and growth potential in Hep-2 cells needs further
investigation.
Viral vector-based delivery is consistently associated
with vector-based shRNA production systems, a DNA-
based strategy to encode and obtain host-synthesized
shRNAs in situ. These shRNAs can be further intracel-
lularly processed into siRNA by Dicer. The viral vector-
based shRNA strategy has the potential of being able to
provide stable, enduring gene silencing. Gene therapy
can in principle continuously generate siRNA [24].
Therefore, we used shRNA against sCLU to study the
effect of sCLU in vivo for its long duration. Our pre-
sented results clearly demonstrate that shRNA targeted
to sCLU mRNA can inhibit the growth of laryngeal can-
cer Hep-2 cells by 73% in vivo, and significantly more
apoptotic cells in the sCLU-shRNA targeted groups,
proved sCLU’s anti-apoptotic potential. Furthermore,
shRNA targeted to sCLU exhibited a significant lung
metastasis model. In the clinical course of laryngeal car-
cinomas, lung metastasis is a very unfavorable develop-
ment that frequently occurs in patients with laryngeal
carcinomas. However, the mechanism of how sCLU
works is still uncertain.In summary, sCLU is a target for therapeutic inhib-
ition in laryngeal carcinomas. The siRNAs (shRNAs)
used in this study are potent tools for modulating the
sCLU gene expression and they may ultimately develop
into attractive antitumor therapeutics.
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